Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.95
- Piotroski Score 4.00
- Grade Outperform
- Symbol (CRBP)
- Company Corbus Pharmaceuticals Holdings, Inc.
- Price $19.16
- Changes Percentage (4.64%)
- Change $0.85
- Day Low $18.02
- Day High $19.48
- Year High $61.90
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $67.00
- High Stock Price Target $82.00
- Low Stock Price Target $40.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.90
- Trailing P/E Ratio -6.4
- Forward P/E Ratio -6.4
- P/E Growth -6.4
- Net Income $-44,603,316
Income Statement
Quarterly
Annual
Latest News of CRBP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts?
The article discusses the bullish investor sentiment towards the market, especially after the Fed's interest rate cut. It analyzes Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) as a top Russell ...
By Yahoo! Finance | 1 month ago -
Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Oppenheimer's top 32 stock picks for the next 12 months include Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), ranking 7th. CRBP is a biotech company with promising drug candidates....
By Yahoo! Finance | 2 months ago -
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price, News, Quote & History - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focusing on developing innovative products for treating serious illnesses. They are working on various drugs targeting cancer cells...
By Yahoo! Finance | 4 months ago
